CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

All Catalyst Types

PDUFA Dates

As of Nov 17, 2026, CatalystAlert tracks 91 upcoming pdufa dates: 64 with the exact day known, the rest estimated by month from sources such as ClinicalTrials.gov and company filings. Next up: SVRA, CAPR, SNY.

FDA target action dates — the deadline by which the FDA must decide on a drug application. The single most-watched binary catalyst in biotech.

These dates are public. The filterable calendar, alerts, exports and AI research are in the app — free account: the next 7 days and 3 companies you track. Plans →

November 202611

5d
CAPRPDUFA
Phase 3

FDA PDUFA Date Deramiocel

Deramiocel (CAP-1002)
Nov 22
Source
00%
5d
SVRAPDUFA
Phase 3

FDA PDUFA Date Molgramostim (MOLBREEVI)

Molgramostim
Nov 22
Source
00%
2w
SNYPDUFA
Phase 3

FDA PDUFA Date Venglustat

Venglustat
Nov 25
Source
00%
2w
BBIOPDUFA
NDA

FDA PDUFA Date BBP-418

BBP-418
Nov 27
Source
00%
2w
GSKPDUFA
Phase 3

FDA PDUFA Date neladalkib (NVL-655)

Neladalkib (NVL-655)
Nov 27
Source
00%
2w
RPRXPDUFA
NDA

FDA PDUFA Date neladalkib (priority)

neladalkib
Nov 27
SEC
00%
2w
BBOTPDUFA
NDA

FDA PDUFA Date BBP-418

BBP-418
Nov 27
Source
00%
2w
PYPDPDUFA
Phase 3

FDA PDUFA Date D-PLEX100

D-PLEX
Nov 28
Source
00%
2w
VRTXPDUFA
Phase 3

FDA PDUFA Date povetacicept

Povetacicept
Nov 30
Source
00%
2w
ZLABPDUFA
NDA

FDA PDUFA Date povetacicept (accelerated)

povetacicept
Nov 30
SEC
00%
2w
COGTPDUFA
Phase 2

FDA PDUFA Date bezuclastinib

bezuclastinib
Nov 30
SEC
00%

December 202613

Dec '26
ANABPDUFA
NDA

FDA PDUFA Date imsidolimab

Dec 2026~
Source
00%
3w
EXELPDUFA
Phase 3

FDA PDUFA Date zanzalintinib

Zanzalintinib
Dec 3
SEC
00%
Dec '26
ALVOPDUFA
NDA

FDA PDUFA Date AVT16 (vedolizumab biosimilar) (standard review)

AVT16 (vedolizumab biosimilar)
Dec 2026~
Source
00%
4w
ANABPDUFA
NDA

FDA PDUFA Date Quimilza

Quimilza
Dec 12
SEC
00%
Dec '26
VNDAPDUFA
Phase 3

FDA PDUFA Date imsidolimab

Imsidolimab
Dec 2026~
SEC
00%
Dec '26
RDYPDUFA
NDA

FDA PDUFA Date abatacept (biosimilar) (standard)

abatacept (biosimilar)
Dec 2026~
SEC
00%
5w
CORTPDUFA
Phase 3

FDA PDUFA Date relacorilant

Relacorilant
Dec 17
SEC
00%
2mo
CAMX.STPDUFA
Phase 3

FDA PDUFA Date CAM2029

CAM2029
Dec 18
Source
00%
2mo
MLYSPDUFA
Phase 3

FDA PDUFA Date lorundrostat

Lorundrostat
Dec 22
Source
00%
Dec '26
HCMPDUFA
Phase 3

FDA PDUFA Date Sovleplenib (priority review)

HMPL-523
Dec 2026~
Source
00%
2mo
VTRSPDUFA
Phase 3

FDA PDUFA Date MR-107A-02 (fast-acting meloxicam)

MR-107A-02
Dec 27
SEC
00%
2mo
PRAXPDUFA
Phase 3

FDA PDUFA Date relutrigine (PRAX-562)

PRAX-562
Dec 27
Source
00%
2mo
COGTPDUFA
Phase 2

FDA PDUFA Date bezuclastinib

bezuclastinib
Dec 30
SEC
00%

January 20277

2mo
NTLAPDUFA
NDA

FDA PDUFA Date (priority review)

Jan 2
Source
00%
2mo
ARGXPDUFA
Phase 3

FDA PDUFA Date efgartigimod alfa-fcab (priority)

Efgartigimod
Jan 3
SEC
00%
3mo
HRMYPDUFA
NDA

FDA PDUFA Date HBS-102 (standard)

HBS-102
Jan 18
SEC
00%
3mo
ETONPDUFA
NDA

FDA PDUFA Date ET-105 (standard)

ET-105
Jan 18
SEC
00%
3mo
DYNPDUFA
Phase 3

FDA PDUFA Date zeleciment rostudirsen (DYNE-251) (priority)

Zeleciment Rostudirsen (DYNE-251)
Jan 21
SEC
00%
3mo
INSMPDUFA
Phase 2

FDA PDUFA Date ARIKAYCE (priority)

Arikayce™
Jan 28
SEC
00%
3mo
PRAXPDUFA
Phase 2

FDA PDUFA Date ulixacaltamide (PRAX-944)

PRAX-944
Jan 29
Source
00%

February 202717

3mo
GILDPDUFA
Phase 3

FDA PDUFA Date Yeztugo (lenacapavir)

Lenacapavir
Feb 2
SEC
00%
3mo
BBIOPDUFA
Phase 3

FDA PDUFA Date Infigratinib (priority)

Infigratinib
Feb 4
SEC
00%
3mo
VSTMPDUFA
NDA

FDA PDUFA Date AVMAPKI FAKZYNJA CO-PACK (Blister Pack) (priority)

AVMAPKI FAKZYNJA CO-PACK (Blister Pack)
Feb 7
SEC
00%
3mo
RHHBYPDUFA
Phase 3

FDA PDUFA Date Lunsumio VELO (mosunetuzumab) in combination with Polivy (polatuzumab vedotin) (accelerated review)

Mosunetuzumab
Feb 9
Source
00%
Feb '27
DCPHPDUFA
Phase 3

FDA PDUFA Date Tirabrutinib

Tirabrutinib
Feb 2027~
Source
00%
3mo
BLTEPDUFA
Phase 3

FDA PDUFA Date Tinlarebant (priority review)

Tinlarebant
Feb 12
Source
00%
Feb '27
REGNPDUFA
Phase 3

FDA PDUFA Date Ordspono (odronextamab)

Odronextamab
Feb 2027~
SEC
00%
Feb '27
ARGXPDUFA
Phase 3

FDA PDUFA Date VYVGART and VYVGART Hytrulo (efgartigimod alfa) (priority)

Efgartigimod
Feb 2027~
SEC
00%
Feb '27
GSKPDUFA
Phase 3

FDA PDUFA Date Jemperli (dostarlimab) (priority)

Dostarlimab
Feb 2027~
SEC
00%
Feb '27
RGNXPDUFA
NDA

FDA PDUFA Date RGX-121 (accelerated review)

RGX-121
Feb 2027~
Source
00%
4mo
ARQTPDUFA
Phase 3

FDA PDUFA Date ZORYVE (roflumilast) cream 0.05% (standard)

Roflumilast
Feb 23
SEC
00%
Feb '27
LRMRPDUFA
Phase 2

FDA PDUFA Date nomlabofusp (accelerated review)

CTI-1601
Feb 2027~
Source
00%
4mo
CGEMPDUFA
Phase 2

FDA PDUFA Date CLN-081 (breakthrough)

CLN-081
Feb 27
SEC
00%
4mo
PVLAPDUFA
NDA

FDA PDUFA Date (priority review)

Feb 28
Source
00%
4mo
LGNDPDUFA
NDA

FDA PDUFA Date Qtorin rapamycin (priority)

Qtorin rapamycin
Feb 28
SEC
00%
4mo
APMDPDUFA
NDA

FDA PDUFA Date AD109 (Oxnimbi) (standard)

AD109 (Oxnimbi)
Feb 28
SEC
00%
4mo
BMRNPDUFA
Phase 2

FDA PDUFA Date Vosoritide (VOXZOGO)

Vosoritide Injection
Feb 28
Source
00%

March 202710

Mar '27
REGNPDUFA
Phase 3

FDA PDUFA Date garetosmab

Garetosmab
Mar 2027~
Source
00%
4mo
EXELPDUFA
Phase 3

FDA PDUFA Date cabozantinib

Cabozantinib
Mar 3
SEC
00%
Mar '27
XENEPDUFA
Phase 3

FDA PDUFA Date azetukalner (standard review)

Azetukalner
Mar 2027~
Source
00%
4mo
NTLAPDUFA
Phase 3

FDA PDUFA Date NTLA-2002 (priority)

NTLA-2002
Mar 10
SEC
00%
4mo
AQSTPDUFA
NDA

FDA PDUFA Date Anaphylm (dibutepinephrine) sublingual film

Anaphylm (dibutepinephrine) sublingual film
Mar 16
SEC
00%
5mo
UNCYPDUFA
Phase 2

FDA PDUFA Date Oxylanthanum Carbonate

Oxylanthanum Carbonate
Mar 25
Source
00%
5mo
AQSTPDUFA
Phase 2

FDA PDUFA Date LIBERVANT (diazepam buccal film) (standard)

Diazepam Buccal Film
Mar 29
SEC
00%
5mo
ETONPDUFA
NDA

FDA PDUFA Date LIBERVANT (diazepam buccal film)

LIBERVANT (diazepam buccal film)
Mar 29
SEC
00%
Mar '27
TEVAPDUFA
NDA

FDA PDUFA Date ecopipam (priority review)

ecopipam
Mar 2027~
Source
00%
5mo
ATRAPDUFA
NDA

FDA PDUFA Date Tabelecleucel (Tab-cel®)

Tabelecleucel (Tab-cel®)
Mar 31
Source
00%

April 20279

5mo
HRMYPDUFA
NDA

FDA PDUFA Date Pitolisant GR

Pitolisant GR
Apr 1
Source
00%
5mo
ALCOX.PAPDUFA
Phase 3

FDA PDUFA Date NCX 470

NCX 470
Apr 1
Source
00%
5mo
JHPCYPDUFA
NDA

FDA PDUFA Date - rivoceranib

Apr 9
Source
00%
5mo
INBXPDUFA
NDA

FDA PDUFA Date Ozekibart (INBRX-109)

Ozekibart (INBRX-109)
Apr 14
Source
00%
5mo
JAZZPDUFA
Phase 2

FDA PDUFA Date oral cannabidiol capsule

Cannabidiol
Apr 16
SEC
00%
6mo
MRKPDUFA
NDA

FDA PDUFA Date IDVYNSO (standard)

IDVYNSO
Apr 22
SEC
00%
6mo
PHVSPDUFA
Phase 3

FDA PDUFA Date deucrictibant (immediate-release, 20 mg) (standard)

Deucrictibant
Apr 23
SEC
00%
6mo
RPRXPDUFA
NDA

FDA PDUFA Date deucrictibant (standard)

deucrictibant
Apr 23
SEC
00%
6mo
IMNMPDUFA
Phase 3

FDA PDUFA Date varegacestat

AL102
Apr 28
SEC
00%

May 202711

6mo
QUREPDUFA
Phase 2

FDA PDUFA Date AMT-130 (priority review)

AMT-191
May 1
Source
00%
6mo
AXSMPDUFA
Phase 3

FDA PDUFA Date AXS-12

AXS-12 (reboxetine)
May 1
Source
00%
6mo
BBIOPDUFA
Phase 3

FDA PDUFA Date encaleret (standard)

Encaleret
May 8
SEC
00%
May '27
RGNXPDUFA
NDA

FDA PDUFA Date Regenxbio gene therapy (unnamed)

Regenxbio gene therapy (unnamed)
May 2027~
Source
00%
6mo
BMYPDUFA
NDA

FDA PDUFA Date mezigdomide

mezigdomide
May 13
SEC
00%
May '27
REPLPDUFA
Phase 2

FDA PDUFA Date RP1

RP1
May 2027~
Source
00%
7mo
RPRXPDUFA
NDA

FDA PDUFA Date tislelizumab (priority)

tislelizumab
May 27
SEC
00%
7mo
ZBIOPDUFA
Phase 3

FDA PDUFA Date Obexelimab

Obexelimab
May 27
SEC
00%
7mo
ETONPDUFA
NDA

FDA PDUFA Date ASN-001

May 28
Source
00%
May '27
RHHBYPDUFA
Phase 3

FDA PDUFA Date fenebrutinib (priority review)

Fenebrutinib
May 2027~
Source
00%
7mo
BMRNPDUFA
NDA

FDA PDUFA Date DMX-200

May 30
Source
00%

June 20276

Jun '27
OCULPDUFA
NDA

FDA PDUFA Date Axpaxli

Axpaxli
Jun 2027~
Source
00%
7mo
URGNPDUFA
Phase 3

FDA PDUFA Date UGN-103

UGN-103
Jun 14
Source
00%
7mo
MRKPDUFA
Phase 3

FDA PDUFA Date sac-TMT (sacituzumab tirumotecan) (standard)

sac-TMT
Jun 15
SEC
00%
Jun '27
JHPCYPDUFA
NDA

FDA PDUFA Date Sumecigrel Capsule

Sumecigrel Capsule
Jun 2027~
Source
00%
8mo
CELCPDUFA
Phase 3

FDA PDUFA Date gedatolisib

Gedatolisib
Jun 25
Source
00%
Jun '27
QUREPDUFA
NDA

FDA PDUFA Date ifezuntirgene inilparvovec (priority review)

ifezuntirgene inilparvovec
Jun 2027~
Source
00%

August 20273

Aug '27
JHPCYPDUFA
Phase 2

FDA PDUFA Date AP301

HS-20093 for Injection
Aug 2027~
Source
00%
Aug '27
CADLPDUFA
Phase 3

FDA PDUFA Date

aglatimagene besadenovec
Aug 2027~
Source
00%
Aug '27
UTHRPDUFA
Phase 3

FDA PDUFA Date Ralinepag

Ralinepag
Aug 2027~
Source
00%

September 20272

Sep '27
HCMPDUFA
NDA

FDA PDUFA Date ORPATHYS plus TAGRISSO (standard review)

ORPATHYS plus TAGRISSO
Sep 2027~
Source
00%
Sep '27
ATRAPDUFA
NDA

FDA PDUFA Date Ebvallo

Ebvallo
Sep 2027~
Source
00%

October 20272

Oct '27
HGZDYPDUFA
Phase 3

FDA PDUFA Date Zemprocitinib

Picankibart
Oct 2027~
Source
00%
Oct '27
ETONPDUFA
NDA

FDA PDUFA Date KHINDIVI

KHINDIVI
Oct 2027~
Source
00%
Get PDUFA Dates Alerts

About PDUFA Dates

A PDUFA date is the deadline by which the U.S. Food and Drug Administration must take action on a New Drug Application (NDA) or Biologics License Application (BLA). It is named after the Prescription Drug User Fee Act, under which companies pay a fee in exchange for the FDA committing to a review timeline.

Standard reviews carry a 10-month goal date (12 months from submission); Priority Review — granted to drugs that offer a significant improvement over existing options — shortens that to 6 months (8 from submission). On or before the PDUFA date the FDA issues one of three outcomes: an approval, a Complete Response Letter (CRL) identifying deficiencies, or, occasionally, an extension of the review clock.

Why PDUFA Dates matter to investors

PDUFA dates are binary, scheduled events, which makes them the most tradable catalyst in biotech. An approval can re-rate a stock overnight; a CRL or unexpected delay can cut a small-cap in half. Because the date is known in advance, options-implied volatility and pre-decision run-ups build around it — which is exactly why investors track a live PDUFA calendar.

Frequently asked questions

What is a PDUFA date?

A PDUFA date is the FDA’s target deadline to decide on a drug application under the Prescription Drug User Fee Act. Standard reviews target 10 months; Priority Reviews target 6 months.

What happens on a PDUFA date?

The FDA issues one of three outcomes: approval, a Complete Response Letter (CRL) listing deficiencies, or an extension of the review period. The decision often arrives on or shortly before the date, and sometimes early.

Do PDUFA dates move stock prices?

Yes — they are binary regulatory events. Approvals frequently drive sharp gains and CRLs or delays sharp losses, so PDUFA dates are among the highest-impact biotech catalysts.

Can a PDUFA date change?

Yes. The FDA can extend the date (commonly by three months) if a company submits a major amendment, or act before it. CatalystAlert labels each date confirmed, estimated, or AI-detected so you know how firm it is.